Prakt. lékáren. 2010; 6(1): 30-35

New medicinal substances in extemporaneous prescription, part 1 - Nystatin

PharmDr.Zbyněk Sklenář, Ph.D.1, PharmDr.Jan Hašek2
1 Vyšší odborná škola zdravotnická, Plzeň
2 Lékárna U Matky Boží, Doksy

Nystatin is a well-known and long-established antifungal drug; in the Czech Republic, however, it has been available exclusively in the form

of mass produced medicinal drugs, not as a substance for magistral preparation. Since this medication is particularly applied in candida

infections of the skin and oral cavity, it should be made available for magistral preparation of medicines in the Czech Republic, too. The

paper aims to introduce the above-mentioned substance in more detail, specify its properties, effects, and use, present some selected

prescriptions used abroad and thus bring them to the attention of both pharmacists and physicians in the Czech Republic. Moreover,

warranted shelf life periods based on the data from standardized prescriptions from abroad are listed for magistral preparations. Nystatin

prescriptions may be modified as required by the prescribing physicians, or new ones may be made provided there is sufficient

stability of the main active substance.

Keywords: nystatin, magistral preparation, candidiasis, neonates, premature infants, stability, anionic cream, gynaecological ointment

Published: March 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sklenář Z, Hašek J. New medicinal substances in extemporaneous prescription, part 1 - Nystatin. Praktické lékárenství. 2010;6(1):30-35.
Download citation

References

  1. Deutscher Arzneimittel-Codex (DAC) 2007/Neues Rezeptur-Formularium (NRF). Band I-III. Pharmazeutischen Laboratorium des NRF. Eschborn: Govi-Verlag und Stuttgart: Deutscher Apotheker-Verlag, 2007.
  2. Deutscher Arzneimittel-Codex (DAC)/Neues RezepturFormularium (NRF). Ergänzung 2008. Pharmazeutischen Laboratorium des NRF. Eschborn: Govi-Verlag und Stuttgart: Deutscher Apotheker-Verlag, 2008.
  3. Mikro-verze AISLP - Automatizovaný informační systém léčivých přípravků. [CD-ROM]. Ver. 2009.4 pro MS Windows platná k 1. 10. 2009.
  4. Český lékopis 2005. 1. vyd. Praha: Grada Publishing, a. s., 2005: 3264 s.
  5. Hartke H, Hartke K. Monographien: Nystatin. In: Hartke K, et al. DAB-Kommentar. Wissenschaftliche Erläuterungen zum Europäischen Arzneibuch 1997. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1997.
  6. Wolf G, Süverkrüp R. Rezepturen Probleme Erkennen, Lösen, Vermeiden. Stuttgart: Deutscher Apotheker Verlag Stuttgart 2002: 192 s.
  7. Adámek F. Informace z materiálů VÚAB Pharma, a.s. (Certifikát o analýze nystatinu), osobní sdělení.
  8. Fadrhoncová A. Farmakoterapie kožních nemocí. 2., přeprac. a rozšíř. vyd. Praha: Grada Publishing s.r.o., 1999: 246 s.
  9. Veselský Z, et al. Mykotické infekce - patofyziologie a patologie postižení urogenitálního traktu. Urolog. pro Praxi 2005; 5(3): 99-102.
  10. Buchta V, Slezák R, Špaček J, Košťálová M, Vejsová M, Doležal M. Současné možnosti léčby kožních a slizničních mykóz. Dermatol. praxi 2009; 3(3): 109-118.
  11. Hoc S. Kandidoseprophylaxe bei Risikoneugeborenen. Krankenhauspharmazie 1993; 14: 44-45.
  12. Normand S, Francois B, Darde ML, et al. Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients. Intensive Care Med 2005; 31: 1508-1513. Go to original source... Go to PubMed...
  13. Rosenberger A, et al. Akute generalisierte exanthemische Pustulose, induziert durch Nystatin. Hautarzt 1998; 49: 492-495. Go to original source... Go to PubMed...
  14. Altmeyer P. Therapielexikon Dermatologie und Allergologie. 2. vyd. Berlin, Heidelberg: Springer-Verlag, 2005: 641 s. Go to original source...
  15. http://www.umm.edu/altmed/drugs/nystatin-093600.htm [cit. 2009-10-18].
  16. K nežádoucím účinkům sloučenin bóru. In: Farmakoterapeutické informace (příloha Věstníku SÚKL). Věstník SÚKL. Praha: Státní ústav pro kontrolu léčiv 1995; 8(9): 8.
  17. Sterry W, Paus R, Burgdorf W. Dermatology. Stuttgart: Thieme, 2006: 696 s.
  18. Čepický P. Praescriptiones magistrales v gynekologii. In: Farmakoterapie v gynekologii. Modern gynekol. porod. 2003; 12(3): 486-487.
  19. Sklenář Z. Inkompatibility v receptuře magistraliter. Prakt Lékáren 2005; 1(1): 31-34.




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.